EUVIMEDEUVIMED entdecken
Open Access

In vitro pharmacological modulation of NKG2D expression in immune cells from Behçet syndrome patients

Martina Bonacini iD, Francesco Muratore, Laura Albertazzi, Luca Cimino, Rossana Colla, Alessandro Zerbini, Carlo Salvarani, Stefania Croci iD

Clinical and Experimental Immunology · 06.01.2026 · 220 (1)

DOI: 10.1093/cei/uxag016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, online erschienen am 18.03.2026. Verfasst von Martina Bonacini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy. Hauptthemen laut MEDLINE: Behcet Syndrome, NK Cell Lectin-Like Receptor Subfamily K. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Association of Patients Affected With Behçet Disease, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocorticoids, interferon-2α, colchicine, and azathioprine are recommended by EULAR for various manifestations of Behçet syndrome (BS). Curcumin is a natural compound with anti-inflammatory activities. NKG2D is a receptor expressed by NK, NKT, and CD8pos T cells implicated in recognizing stressed cells. This study aimed to: (i) evaluate the effects of selected drugs used in the management of BS plus curcumin on NKG2D expression by lymphocytes; (ii) test the effects of these drugs on immune cell subsets; and (iii) determine whether immune cells from BS patients respond differently to those from healthy controls (CTR). Peripheral blood mononuclear cells from BS patients and CTR were treated with dexamethasone, interferon-2α, colchicine, azathioprine, or curcumin for 48 h in the presence or absence of IL-15. NKG2D expression on NK, NKT, and CD8pos T cells and the percentages/absolute counts of NK, NKT, T, and B cells were evaluated by flow cytometry. All drugs down-regulated NKG2D expression. The reduction was more pronounced in CTR than in BS patients following dexamethasone treatment, in BS patients than in CTR following colchicine treatment. Dexamethasone reduced NK cells in the absence of IL-15, but increased them in its presence. Colchicine reduced B cells regardless of IL-15 stimulation. Azathioprine also down-regulated B cells, but only in the presence of IL-15 stimulation. Drugs used in the management of BS reduced NKG2D expression, potentially decreasing the activation of cytotoxic cells. Immune cells from BS patients responded differently to dexamethasone and colchicine compared to those from CTR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeNK Cell Lectin-Like Receptor Subfamily KHumansFemaleAdultColchicineKiller Cells, NaturalAzathioprineDexamethasoneMaleNatural Killer T-CellsInterferon-alphaInterleukin-15CD8-Positive T-LymphocytesMiddle AgedB-LymphocytesCells, Cultured

Stichwörter der Autor:innen

Behçet syndromeNKG2Dazathioprinecolchicinedexamethasoneinterferon-2α

Substanzen

NK Cell Lectin-Like Receptor Subfamily KColchicineAzathioprineDexamethasoneKLRK1 protein, humanInterferon-alphaInterleukin-15

Autor:innen und Institutionen

  • Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Unit of Rheumatology, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Department of Surgery, Medicine Dentistry and Morphological Sciences with Interest in Transplant, University of Modena and Reggio Emilia, Modena, Italy.
  • Chemical-Clinical Analysis Laboratory, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
  • Unit of Ocular Immunology, Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

ORCID-Profile: Martina Bonacini, Stefania Croci

Förderung

  • National Association of Patients Affected With Behçet Disease
  • Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia
  • Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia

Zitieren

APA

Bonacini, M., Muratore, F., Albertazzi, L., Cimino, L., Colla, R., Zerbini, A., Salvarani, C., & Croci, S. (2026). In vitro pharmacological modulation of NKG2D expression in immune cells from Behçet syndrome patients. Clinical and Experimental Immunology, 220(1). https://doi.org/10.1093/cei/uxag016

Vancouver

Bonacini M, Muratore F, Albertazzi L, Cimino L, Colla R, Zerbini A, et al. In vitro pharmacological modulation of NKG2D expression in immune cells from Behçet syndrome patients. Clinical and Experimental Immunology. 2026;220(1). doi:10.1093/cei/uxag016

BibTeX
@article{Bonacini2026,
  author = {Bonacini, Martina and Muratore, Francesco and Albertazzi, Laura and Cimino, Luca and Colla, Rossana and Zerbini, Alessandro and Salvarani, Carlo and Croci, Stefania},
  title = {In vitro pharmacological modulation of NKG2D expression in immune cells from Behçet syndrome patients},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  volume = {220},
  number = {1},
  doi = {10.1093/cei/uxag016}
}
Kostenlos starten →